Neogenomics (NEO) PT Lowered to $17 at BTIG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
NeoGenomics Reports Fourth Quarter and Full Year 2024 Results
February 18, 2025 7:05 AM EST
Full Year Revenue Increased 12% to $661 million;
Ninth Consecutive Quarter of Double-Digit Revenue Growth
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (Nasdaq: NEO) (the Company), a leading oncology testing services company, today announced its fourth-quarter and full year results for the period ended December 31, 2024.
Fourth Quarter and Full Year 2024... More
